MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to find a safe dose and check for side effects. Re…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
CAR-T therapy Follow-Up study finds no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various blood cancers like lymphoma and leukemia. The goal was to see if any new or late side effects appeared over time and how long the treatment's effects lasted. It was …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC